[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tobacco-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tobacco-use":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,49,0,25,[9,49,78,104,142,173,197,221,239,267,292,314,346,365,386,409,426,453,483,503,526,559,585,602,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605907","a-community-health-worker-intervention-to-improve-lung-cancer-screening-uptake-in-community-health-centers-100605907",false,"NCT07168629","A Community Health Worker Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers","CHATS","Inclusion Criteria:\n\n* Adults between the age of 50 and 80.\n* Potentially eligible for LCS according to the Electronic Health Record smoking history.\n* Receive their primary care at Mason Square, High Street, or Brightwood community health centers.\n* English- or Spanish- speaking.\n\nExclusion Criteria:\n\n* Not eligible for lung cancer screening based on age (age \\\u003C 50 or \\> 80 years) or smoking history (has not smoked more than 20 pack-years of tobacco cigarettes or quit more than 15 years ago).\n* Have received a lung cancer screen in the past.",true,"ALL","50 Years","80 Years",{"count":22,"type":23},80,"ESTIMATED","INTERVENTIONAL",[26],"NA","Lung cancer screening (LCS) can reduce lung cancer-related mortality by 20%, but only 5-10% of eligible individuals have received an initial LCS. The goal of this study is to partner with community stakeholders to jointly develop and pilot test a multi-component community health worker-delivered intervention targeting key barriers to improve LCS and tobacco treatment utilization. The proposed activities will lay the groundwork for a subsequent R01 grant, conducting a fully powered randomized clinical trial to establish CHWs as an evidence-based practice that will facilitate access to screening and tobacco treatment, to reduce lung cancer mortality.",[29,30],"Lung Cancer","Tobacco Use",[32,33,34,35],"lung cancer screening","tobacco treatment","community health workers","community health centers","RECRUITING","2026-08-19",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":42,"type":40},"2026-05-10",{"date":44,"type":23},"2028-08-01",{"name":46,"class":47},"Baystate Medical Center","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100651235","the-effect-of-motivational-interviewing-on-smoking-behavior-among-nursing-students-100651235","NCT07758998","The Effect of Motivational Interviewing on Smoking Behavior Among Nursing Students","The Effect of Motivational Interviewing on Changing Smoking Behavior Among Nursing Students","Inclusion Criteria:\n\n* Nursing students currently enrolled in the study setting.\n* Aged 18 years or older.\n* Current cigarette smokers.\n* No self-reported health condition that would prevent participation in the intervention.\n* Willing and able to provide informed consent and participate in the study.\n\nExclusion Criteria:\n\n* Inability to complete all planned stages of the study.\n* Withdrawal of consent or voluntary discontinuation from the study at any time.","18 Years",{"count":58,"type":23},87,[26],"Smoking is one of the leading preventable public health problems worldwide, particularly among young adults who are at increased risk of nicotine dependence. Nursing students represent an important target population because, as future health professionals, they are expected to play a significant role in tobacco control and smoking cessation counseling. The Transtheoretical Model (TTM) is one of the most widely used theoretical frameworks for promoting health behavior change. The aim of this study will be to determine the effect of Transtheoretical Model-based motivational interviewing on changing smoking behavior among nursing students.\n\nThis study will be planned as a single-group, quasi-experimental pretest-posttest intervention. Nursing students who smoke cigarettes and voluntarily agree to participate will be included in the study. At baseline, participants will complete a Demographic Information Form, the Fagerström Test for Nicotine Dependence, the Stages of Change questionnaire, the Self-Efficacy\u002FTemptation Scale, the Processes of Change Scale, and the Decisional Balance Scale.\n\nParticipants will receive Transtheoretical Model-based educational sessions and motivational interviewing interventions focusing on the health effects of smoking, reasons for smoking, the benefits of smoking cessation, identification of social support resources, relapse prevention strategies, and successful smoking cessation experiences. The Stages of Change questionnaire will be administered before each motivational interviewing session, and all outcome measures will be reassessed during follow-up evaluations. The study is expected to provide evidence regarding the effectiveness of Transtheoretical Model-based motivational interviewing in reducing smoking behavior, decreasing nicotine dependence, promoting progression through the stages of change, improving self-efficacy, enhancing the use of behavioral change processes, and supporting smoking cessation among nursing students.",[30,62],"Smoking Cessation",[64,65,66,62,30,67],"motivational interviewing","Transtheoretical Model","Nursing Students","Smoking Behavior","NOT_YET_RECRUITING","2026-08-10",{"date":71,"type":40},"2026-08-11",{"date":73,"type":23},"2026-08",{"date":75,"type":23},"2026-12",{"name":77,"class":47},"Meral Feratoğlu Research",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":48},"100649272","adaptation-and-testing-of-a-novel-text-based-tobacco-cessation-and-education-intervention-in-kenyan-emergency-department-patients-100649272","NCT07734727","Adaptation and Testing of a Novel Text-based Tobacco Cessation and Education Intervention in Kenyan Emergency Department Patients","Text2Quit","Inclusion Criteria:\n\n* Current tobacco users (self-identified smokers).\n* Presenting to the Emergency Department (ED) at Kenyatta National Hospital (KNH).\n* Own a mobile phone capable of receiving text messages.\n* Willing to quit tobacco use.\n* Able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Individuals unwilling or unable to provide consent.\n* Non-tobacco users.\n* Those without access to a mobile phone.\n* Patients who are critically ill or otherwise unable to participate (practically excluded at triage).",{"count":86,"type":23},285,[26],"In this study, investigators will adapt and implement Text2Quit in a Kenyan ED population will increase knowledge and cessation. Investigators will use a mixed-methods, hybrid implementation-effectiveness approach to assess these outcomes. Results will inform a randomized, controlled trial in a nationally representative sample of EDs in future. This study will be the first to target tobacco use in this population, the first to use mobile cessation, and will contribute to advancing implementation science on tobacco cessation globally. It will also provide a novel approach to implementation for mHealth interventions, with findings that can be generalized to other Non-Communicable Diseases and risk factors, such as alcohol use, hypertension and diabetes.",[30,90],"Tobacco Use Cessation",[92,93,94,95],"Kenya","Africa","Noncommunicable disease","global health","2026-08-04",{"date":98,"type":40},"2026-08-06",{"date":73,"type":23},{"date":101,"type":23},"2028-06",{"name":103,"class":47},"Yale University",{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":113,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":48},"100650370","just-in-time-support-for-smoking-vaping-and-eating-urges-during-high-stress-moments-among-gender-and-sexual-minority-adults-in-dhaka-100650370","NCT07746492","Just-in-Time Support for Smoking, Vaping, and Eating Urges During High-Stress Moments Among Gender and Sexual Minority Adults in Dhaka","A Digital Real-Time Support for Stress-Induced Smoking and Unhealthy Eating Among Gender and Sexual Minorities in Dhaka","Inclusion Criteria:\n\n* Age 18 years or older\n* Self-identifies as a gender and\u002For sexual minority person\n* Resides in Dhaka at enrolment and expects to remain in Dhaka throughout the 24-day assessment period\n* Reports at least one qualifying behaviour on average at least 3 days per week during the past month: (a) smoking or vaping, or (b) eating primarily in response to stress, anxiety, or emotional distress\n* Owns a personal Android or iOS smartphone compatible with the study platform that is used solely by the participant and is not shared with others\n* Able to read, understand, and respond to simple Bangla text\n* Able to operate the study app independently after a structured onboarding session\n* Willing to complete five scheduled app-based momentary assessments per day for 24 days and additional brief follow-up assessments after randomized decision points\n* Provides written informed consent\n\nExclusion Criteria:\n\n* Currently participating in another behavioural or pharmacological intervention study targeting smoking, vaping, or eating behaviour\n* Has a severe or unstable psychiatric condition that, based on screening and review by the study clinician, would make participation in the repeated daily assessment protocol unsafe\n* Is unable to operate the study app independently after structured onboarding",{"count":112,"type":23},115,[26],"Gender and sexual minority adults in Bangladesh experience high levels of stigma-related stress. Acute stress can trigger strong, affect-driven urges to smoke, vape, or engage in stress-attributed eating. These urges can rise and fall within minutes to hours, operating outside the reach of conventional clinic-based interventions delivered days or weeks later.\n\nThis pilot micro-randomized trial (MRT) evaluates whether delivering a brief, culturally adapted support message via smartphone during moments of high self-reported stress reduces the intensity of the urge for the participant's pre-specified target behaviour, relative to no message. Over a 24-day period, 115 participants will be scheduled for up to 5 ecological momentary assessments (EMA) per day. Whenever a participant reports an acute stress level of 5 or higher (0 to 10 scale) and satisfies pre-specified privacy, safety, behavioural, and spacing criteria, the app randomizes with probability 0.5 to deliver either a brief support message or no message. By contributing multiple randomized decision points over time, each participant serves as their own micro-control.\n\nThe primary outcome is the intensity of the urge for the participant's pre-specified target behaviour, measured 45 to 60 minutes after randomization. An exploratory urge assessment is also collected 10 minutes after randomization; comparing the two time points will help establish whether the support message's effect is immediate, delayed, or both, and will inform the choice of follow-up window for a future, fully powered trial. Prior to trial launch, all EMA items, message content, notification logic, and digital safety protocols will be developed and tested with community members, reviewed by a Community Advisory Board, and locked.\n\nAs a pilot optimization trial, its objectives are to estimate the short-term causal effect of the prompt, to identify the contexts in which that effect is larger or smaller, and to establish whether momentary assessment and just-in-time intervention research can be delivered safely, privately, and acceptably in this high-stigma setting. The study does not evaluate long-term behavioural maintenance and does not claim to address the underlying structural stigma and discrimination that produce minority stress.",[30,116,117,118],"Electronic Cigarette Use","Emotional Eating","Stress, Psychological",[120,121,122,123,124,125,126,127,128,129,130,131,132],"micro-randomized trial","just-in-time adaptive intervention","ecological momentary assessment","mHealth","digital health","minority stress","smoking","vaping","stress-attributed eating","urge","Bangladesh","gender and sexual minority","pilot optimization trial","2026-07-30",{"date":135,"type":40},"2026-08-05",{"date":137,"type":23},"2026-09-01",{"date":139,"type":23},"2027-02-06",{"name":141,"class":47},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100647858","puff-topography-and-sensory-effects-across-iqos-device-generations-100647858","NCT07712887","Puff Topography and Sensory Effects Across IQOS Device Generations","Puff Topography and Sensory Effects Across IQOS Device Generations: A Randomized Crossover Study","Inclusion Criteria:\n\n* Current IQOS user (at least 3 days per week in the past 30 days)\n* Age 18 to 65 years\n* Generally healthy\n* Willing to provide informed written consent\n* Willing to attend all laboratory visits\n* Willing to abstain from all nicotine and tobacco products for at least 12 hours before each visit\n\nExclusion Criteria:\n\n* Use of any tobacco products other than IQOS in the past 30 days\n* Chronic cardiovascular conditions, seizures, or abnormal blood pressure\n* Current psychiatric disorder requiring active treatment, including major depressive disorder\n* Regular use of prescription medications that may influence cardiovascular function, respiratory function, or nicotine metabolism (excluding vitamins or birth control)\n* Use of cocaine, opioids, benzodiazepines, or methamphetamines in the past month\n* Marijuana use on more than 15 days per month\n* Current pregnancy or breastfeeding\n* Plans to quit nicotine or tobacco products within the next 30 days","65 Years",{"count":151,"type":23},50,[26],"The goal of this clinical trial is to learn how people use two generations of IQOS heated tobacco devices and how each device affects their smoking behavior and sensory experience.\n\nThe main questions it aims to answer are:\n\n* Do participants puff differently when using the newer IQOS Iluma i compared to the older IQOS 2.4?\n* Does the flavor of the tobacco stick (preferred flavor vs. standard tobacco flavor) affect puffing behavior or sensory experience?\n* What are the differences in throat hit, mouthfeel, and satisfaction between the two devices?\n\nParticipants will:\n\n* Attend 2 laboratory visits at the American University of Beirut\n* Use both the IQOS Iluma i and IQOS 2.4 devices during each visit\n* Have their puffing behavior recorded automatically during device use\n* Provide a breath sample before and after each use session\n* Complete short questionnaires about how each device felt and their urge to smoke",[155,30],"Nicotine Dependence",[157,158,159,160,161,162,163],"Heated Tobacco Products","IQOS","Puff Topography","Electronic Nicotine Delivery Systems","Nicotine","Subjective Effects","Tobacco Harm Reduction","2026-07-29",{"date":133,"type":40},{"date":167,"type":40},"2026-07-27",{"date":169,"type":23},"2027-12-15",{"name":171,"class":47},"American University of Beirut Medical Center",2,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":20,"enrollmentInfo":179,"targetDuration":4,"studyType":24,"phases":181,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":172},"100576826","phase-3-optimizing-treatment-of-co-occurring-smoking-and-unhealthy-alcohol-use-among-pwh-in-nairobi-kenya-100576826","NCT06790342","Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya","Inclusion Criteria:\n\n1. Confirmed chart diagnosis of HIV\n2. At least 18 years or age\n3. Currently self-reports smoking (has smoked a cigarette within the past 7 days) and has expired air Carbon Monoxide (CO) 6ppm. Expired air CO provides an accurate indirect measure of carboxyhemoglobin (COHb) level and is a standard biochemical method for assessing a smoker's level of intake.\n4. Motivation to quit smoking within the next 6 months (score 6-8 on the Abrams and Biener Readiness to Quit Ladder)\n5. Meets criteria for heavy drinking: National Institute on Alcohol Abuse and Alcoholism (NIAAA) guidelines suggest gender-based criteria for heavy drinking but note that lower thresholds may be needed for people with a medical condition. PWH show increased physiologic injury and decreased survival at lower levels of alcohol consumption than those without HIV. Thus, we will use the lower limit for alcohol misuse\u002Fheavy drinking from the NIAAA guidelines for all study candidates, i.e. drinking 4+ drinks on a given day or \\>7 drinks\u002Fweek over the past 30 days\n6. Able to speak English (in Nairobi spoken English is near universal as English is an official language of Kenya)\n7. Willingness to accept behavioral and\u002For pharmacologic tobacco and alcohol treatment\n8. Willingness and ability to provide informed consent to participate.\n\nExclusion Criteria:\n\n1. Current receipt of any tobacco or alcohol use behavioral or pharmacologic treatment\n2. Previous allergic reaction or hypersensitivity to cytosine (CYT) (unlikely since CYT is not available in Kenya)\n3. History of severe alcohol withdrawal symptoms in the past 12 months, including seizure or hallucinations\n4. Pregnant, nursing, or becoming pregnant during the study\n5. Current use of any medication that would interfere with the protocol in the opinion of the Medically Accountable Physician\n6. Meets criteria for possible dementia by scoring below 10 on the Hopkins HIV Dementia Scale\n7. Unstable psychiatric illness\n8. Known plans to re-locate or travel away from the study site for more than two consecutive months during the study period\n9. Expected survival of less than 6 months.",{"count":180,"type":23},300,[182],"PHASE3","People with HIV (PWH) smoke tobacco cigarettes and drink alcohol at higher rates than the general population, both in the US and internationally, including low- and middle-income countries. Now that effective antiretroviral therapy is available throughout most of the world, PWH are surviving long enough to manifest the lethal consequences of both their smoking and drinking. In this project, the investigational team aims to advance the knowledge and understanding of treatment strategies (i.e. individual intensive counseling ± pharmacotherapy with cytisine) that target both tobacco and alcohol use among PWH in Kenya, a resource constrained environment, and to generate outcome data that may benefit co-users of tobacco and alcohol throughout the world.",[185,30,186],"HIV","Alcohol Use Disorder",[185,188,189],"Tobacco Cessation","Alcohol Reduction",{"date":133,"type":40},{"date":192,"type":23},"2026-07-31",{"date":194,"type":23},"2029-06-01",{"name":196,"class":47},"University of Chicago",{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":17,"sex":18,"minAge":204,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100649748","a-study-to-assess-nicotine-uptake-from-electronic-nicotine-delivery-system-products-100649748","NCT07739797","A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products","An Open-Label, Randomized, 8-way Crossover Study to Assess Elements of Abuse Liability Electronic Nicotine Delivery System Products in Adult Smokers","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n3. Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n4. Positive urine cotinine test at Screening.\n5. Smokes combustible filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n6. Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n7. Participants must meet one (a or b) of the following tobacco use conditions:\n\n   a. Sole smoker of filtered menthol or non-menthol cigarettes who self reports: i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of an investigator b. Dual user of cigarettes and ENDS who self-reports: i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of an investigator, and ii. Using a nicotine-containing ENDS (cartridge or a tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco, and modern oral nicotine products) on no more than one day per week will not be excluded from study participation.\n8. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n9. Willing to use only UB cigarettes and ENDS IPs during the study period.\n10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n11. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing informed consent until End-of-Study. Examples of acceptable means of birth control include, but are not limited to:\n\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. Physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. Non-hormone releasing intrauterine devices (IUDs) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n    4. Vasectomized partner;\n    5. Post-menopausal and not on hormone replacement therapy; or\n    6. Sexual abstinence, defined as refraining from intercourse, when this is in line with the preferred and usual lifestyle of the participant.\n12. Males must use an acceptable method of birth control from Day -1 \"check-in\" until the end of the study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n13. Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n2. History, presence of, or clinical laboratory test results indicating diabetes.\n3. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening and at check-in Day -1.\n4. Weight of ≤ 110 pounds (≤ 50.0 kg) at Screening.\n5. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C13.0 g\u002FdL for males at Screening.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator's discretion.\n7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco products other than cigarettes or ENDS within the last 6 months prior to screening.\n10. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n11. History or presence of bleeding or clotting disorders.\n12. Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n13. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and check-in Day -1.\n\n    NOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n14. Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and check-in Day -1.\n\n    NOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n15. Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n16. Females who have a positive pregnancy test at Screening or check-in on Day -1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n17. Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n18. A positive drug screen or alcohol test (urine or breath) at Screening or at check-in (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in, a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n19. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n20. Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by an investigator, or has a positive alcohol test at Screening or check-in on Day -1.\n21. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n22. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n23. Determined by an investigator to be inappropriate for this study.","21 Years","60 Years",{"count":151,"type":23},[26],"This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]), and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of electronic nicotine delivery system (ENDS) investigational products (IPs). The study will be conducted in a confinement setting among generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.",[210,211,30],"Smoking Behaviors","Smoking ( Cigarette)","2026-07-28",{"date":192,"type":40},{"date":215,"type":23},"2026-10-01",{"date":217,"type":23},"2027-04",{"name":219,"class":220},"RAI Services Company","INDUSTRY",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":235,"leadSponsor":237,"locationsCount":4},"100649376","automating-tobacco-cessation-in-primary-care-100649376","NCT07735286","Automating Tobacco Cessation in Primary Care","Automating Tobacco Cessation in Primary Care Via EHR Integration: A Non-Randomized Trial","Inclusion Criteria:\n\n* Age 18 years or older\n* Patient at Penn Family Care or Edward Cooper Internal Medicine\n* Had an eligible scheduled or completed practice visit categorized as a new annual visit, return patient visit, return annual visit, or return patient sick visit\n* For the tobacco cessation intervention: Penn Family Care patient who had not previously completed the tobacco questionnaire\n* For the 30-day follow-up survey: Active smoker in the EHR as of the completed visit date or prescribed nicotine replacement therapy (NRT) between 3 days before and 30 days after the completed visit date\n* For the primary analysis: Active smoker in the EHR as of the completed visit date\n* For the primary analysis: Did not have an NRT prescription between 34 and 4 days before the completed visit date\n\nExclusion Criteria:\n\n* None except as specified in inclusion criteria.",{"count":229,"type":23},4800,[26],"This study focuses on improving how primary care teams identify patients who smoke and offer access to nicotine replacement therapy, or NRT. NRT includes medications such as nicotine patches, gum, or lozenges that can reduce cravings and support people who are interested in cutting back or quitting smoking. Although NRT is an evidence-based treatment option, it is not always discussed or prescribed during routine primary care visits. To better understand how NRT can be offered in primary care, the project will test a workflow at Penn Family Care that identifies patients who currently smoke and provides information about available tobacco treatment options. Edward Cooper Internal Medicine will serve as a comparison site. Patients who smoke and\u002For are prescribed NRT will also receive a 30-day follow-up survey to learn whether they received, picked up, or used NRT; whether it was useful; and what barriers they experienced.",[30,90],{"date":164,"type":40},{"date":137,"type":23},{"date":236,"type":23},"2027-08-01",{"name":238,"class":47},"University of Pennsylvania",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":24,"phases":249,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":265,"locationsCount":48},"100610643","telegram-messenger-support-for-smoking-cessation-after-heart-attack-100610643","NCT07230249","Telegram Messenger Support for Smoking Cessation After Heart Attack","Effect of a Behavioral Intervention Delivered Via Telegram Messenger on Smoking Cessation in Patients After Myocardial Infarction: The TELEGRAM-MI Randomized Controlled Trial","TELEGRAM-MI","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 years or older.\n* Hospitalization with a confirmed diagnosis of acute myocardial infarction (MI), including both ST-elevation MI (STEMI) and non-ST-elevation MI (NSTEMI).\n* Current smoker at the time of index MI: self-reported smoking of at least one cigarette per day in the month prior to hospitalization.\n* Regular user of the Telegram messenger application (app installed on a personal smartphone).\n* Possession of a smartphone with internet access and a valid phone number.\n* Ability and willingness to provide contact information for a close relative or cohabiting person who can verify smoking status at follow-up.\n\nExclusion Criteria:\n\n* Smoking cessation more than 1 month prior to the index MI hospitalization.\n* Physical or cognitive impairment that prevents the use of a smartphone (e.g., severe visual\u002Fhearing impairment, inability to read or respond to messages).\n* Inability to read and understand the Russian language fluently.\n* Comorbid condition with a life expectancy of less than 1 year.\n* Active severe mental illness (e.g., psychosis, severe untreated depression) that would impede understanding of the protocol or adherence.\n* Unwillingness or inability to provide contact details for a close relative for outcome verification.",{"count":248,"type":23},142,[26],"This randomized controlled trial will evaluate whether a 6-month behavioral intervention delivered via Telegram messenger increases smoking cessation rates in patients after myocardial infarction (MI).\n\nAdult smokers hospitalized with acute MI who regularly use Telegram will be randomly assigned to either:\n\n* INTERVENTION GROUP: Standard care plus a 6-month Telegram chatbot program providing personalized motivational messages, cognitive-behavioral techniques for craving management, and relapse prevention support.\n* CONTROL GROUP: Standard care (routine physician advice to quit smoking) plus basic surveys via Telegram without therapeutic content.\n\nThe primary outcome is 30-day point prevalence abstinence at 6 months, verified by blinded telephone interview with participant and corroborating report from a close relative. Secondary outcomes include changes in cigarette consumption, nicotine dependence, motivation, and intervention engagement metrics.\n\nThis study addresses the critical gap in smoking cessation support after hospital discharge and could provide evidence for a scalable digital health solution in cardiac secondary prevention.",[252,30,62],"Myocardial Infarction (MI)",[254,255,256,257,258,259,260],"Telegram","Chatbot","Digital Health","Behavioral Intervention","Secondary Prevention","Randomized Controlled Trial","Cardiac Rehabilitation","2026-07-26",{"date":212,"type":40},{"date":167,"type":23},{"date":236,"type":23},{"name":266,"class":47},"ITMO University",{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":24,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":48},"100632584","a-mindfulness-based-intervention-for-sexual-assault-survivors-100632584","NCT07515586","A Mindfulness-based Intervention for Sexual Assault Survivors","Leveraging Implementation Science to Develop a Mindfulness-Based Intervention to Reduce Alcohol Misuse and Tobacco Use Among Sexual Violence Survivors","Inclusion Criteria:\n\n* 18-24 years of age\n* currently enrolled as a full-time undergraduate at GSU\n* self-reported lifetime SV victimization\n* self-reported SV victimization in the past 6 months\n* drank alcohol within the last 30 days\n* must own a smartphone\n\nExclusion Criteria:\n\n* not applicable","24 Years",{"count":276,"type":23},120,[26],"The goal is this pilot randomized trial is to learn if intervention 1 is feasible and acceptable. A secondary aim is to learn if intervention 1 reduces alcohol misuse and tobacco use in sexual assault survivors. The main questions it aims to answer are:\n\n* Is intervention 1 feasible to implement?\n* Is intervention 1 an acceptable intervention among the primary population, sexual assault survivors?\n* Does intervention 1 reduce alcohol misuse and tobacco use?\n\nResearchers will compare intervention 1 to an attention-placebo control group (e.g., online resources on healthy eating and nutrition).\n\nParticipants will:\n\n* take online surveys at baseline, 1 month follow-up, and 3-month follow-up\n* answer text-message questions at baseline and post-test\n* view and engage in an educational program",[280,30,281,282],"Alcohol Misuse","Mindfulness","Stress","2026-07-15",{"date":285,"type":40},"2026-07-16",{"date":287,"type":23},"2027-10-04",{"date":289,"type":23},"2029-03-30",{"name":291,"class":47},"Georgia State University",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":24,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":172},"100518673","phase-3-motivational-interviewing-and-mindfulness-oriented-recovery-enhancement-100518673","NCT06033599","Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement","Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment","Inclusion Criteria:\n\n* English-speaking\n* Age ≥18\n* Currently on methadone; and 4) currently smoke cigarettes.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (score \\>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)\n* Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)\n* Inability to attend or fully participate in intervention sessions or assessments\n* Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33\n* Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling\n* Any contraindications for NRT\n* Currently or soon planning to be pregnant or breastfeeding.",{"count":300,"type":23},420,[182],"The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.",[304,305,30],"Polysubstance Abuse","Opioid Use",{"date":307,"type":40},"2026-07-17",{"date":309,"type":40},"2023-09-05",{"date":311,"type":23},"2028-08",{"name":313,"class":47},"Rutgers, The State University of New Jersey",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":322,"minAge":56,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":48},"100630574","feasibility-and-acceptability-trial-to-reduce-tobacco-and-cannabis-use-during-pregnancy-and-postpartum-100630574","NCT07489443","Feasibility and Acceptability Trial to Reduce Tobacco and Cannabis Use During Pregnancy and Postpartum","Partnering With Pregnant and Postpartum People to Co-Create a Novel Intervention to Reduce Tobacco and Cannabis Use","PICTURe","Inclusion Criteria:\n\n* Confirmed pregnant\n* Under 26 weeks gestation\n* Plan to remain pregnant\n* English speaking\n* Use of combustible tobacco at least once a week during pregnancy, or at least once a week in the 3 months before pregnancy if stopped\n* Use of cannabis at any frequency during pregnancy or in the 3 months before pregnancy if stopped\n\nExclusion Criteria:\n\n* Current opioid use or active treatment for Opioid Use Disorder\n* Unable to provide informed consent in English\n* Under 18 years old","FEMALE",{"count":7,"type":23},[26],"Using both tobacco and cannabis during pregnancy is more common in minoritized groups and can make quitting smoking in pregnancy and remaining smoke free postpartum difficult. Investigators will test an intervention to address prenatal depressive symptoms to encourage people to quit tobacco and cannabis during pregnancy and stay quit postpartum.",[327,328,30,62],"Perinatal","Cannabis Use",[330,331,332,126,333,334,335,336],"tobacco","perinatal","pregnancy","cessation","postpartum","cannabis","intervention","2026-07-01",{"date":339,"type":40},"2026-07-06",{"date":341,"type":40},"2026-06-17",{"date":343,"type":23},"2027-10",{"name":345,"class":47},"University of Pittsburgh",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":4,"eligibilityCriteria":352,"healthyVolunteers":17,"sex":18,"minAge":204,"maxAge":205,"enrollmentInfo":353,"targetDuration":4,"studyType":24,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100646894","abuse-liability-of-four-modern-oral-nicotine-products-100646894","NCT07685795","Abuse Liability of Four Modern Oral Nicotine Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Four Modern Oral Nicotine Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use MST. Participant's usual brand MST product needs to be a moist snuff tobacco product and not a Snus oral tobacco product.\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (occurring 30 days prior to Screening), or clinical study participation (occurring 30 days prior to Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of MST products and agrees to use the same UB MST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n9. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) at Screening and at Check-in Day 1.\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of six Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of seven days (six nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system (e.g., Vuse Alto, JUUL) or tobacco heating device (e.g., iQOS) within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent form.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.",{"count":151,"type":23},[26],"This is a single-site, open-label, randomized, 6-way crossover study designed to evaluate elements of abuse liability (AL) including subjective effects, physiological measures (pharmacodynamics \\[PD\\]), and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[357,210,30,358],"Smoking","Tobacco Smoking","2026-06-29",{"date":339,"type":40},{"date":283,"type":23},{"date":363,"type":23},"2027-01-31",{"name":219,"class":220},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":204,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":24,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":382,"leadSponsor":384,"locationsCount":48},"100642355","impact-of-electronic-cigarette-temperature-and-solvent-on-biomarkers-100642355","NCT07612696","Impact of Electronic Cigarette Temperature and Solvent on Biomarkers","Clinical Study on the Impact of Electronic Cigarette Temperature and Solvent on Biomarkers of Oxidant Exposure","Inclusion Criteria:\n\n* 21 years of age or older\n* Normal pulmonary and cardiovascular function with no history of COPD or cardiovascular disease (excluding hypertension)\n* Current exclusive use of a sub-ohm\u002Fmod or pod EC devices (≥ 1mL e-liquid\u002Fper day, ≥6 mg\u002Fml nicotine concentration, EC for ≥ 1 year)\n* No plan on quitting nicotine use over the course of the study\n* All other forms of nicotine must be used \\\u003C5 days out of the past 28 days.\n* Able to read and write in English\n* Have access to email and a smartphone\u002Fcomputer that has reliable internet connection\n\nExclusion Criteria:\n\n* Women who are pregnant and\u002For nursing or trying to become pregnant\n* Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n* Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n* Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n* Have immediate family or household members currently participating in this trial",{"count":151,"type":23},[26],"This project seeks to determine how e-cigarette (EC) physical design features, including those that allow the user to manipulate the quality and quantity of aerosols, affect exposure and toxicity from oxidants and other aerosol constituents.",[376,30,377],"Oxidative Stress","Electronic Cigarettes","2026-06-12",{"date":380,"type":40},"2026-06-16",{"date":283,"type":23},{"date":383,"type":23},"2028-12",{"name":385,"class":47},"Milton S. Hershey Medical Center",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":393,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":408},"100601259","symptoms-and-functions-in-patients-with-copd-and-chronic-bronchitis-switching-from-cig-to-ths-100601259","NCT07108166","Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS","A Randomized, Single (Operator)-Blinded, Controlled Clinical Study for Assessing Major Symptoms and Function in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis Who Switch From Combustible Cigarettes (CIG) to Tobacco Heating System (THS)","Inclusion Criteria:\n\n* Adult, both sexes, aged ≥ 40 years.\n* Patient has read, understood, and signed the written informed consent form (ICF), which has received IEC or IRB approval.\n* Patient with body mass index (BMI) 17.6-40.0 kg\u002Fm2 and body weight \\> 50 kg (male) or \\> 40 kg (female). Checked at V1 and V2.\n* Patient has a CIG smoking history ≥ 10 years.\n* Patient has been smoking ≥ 10 commercially available and\u002For roll-your-own CIG\u002Fday on average (no brand restriction) for at least the last year (based on self-reporting). Smoking status will be verified by Urine cotinine test (UCOT) ≥200 ng\u002FmL. Intermittent CIG smoking abstinence, with or without Smoking Cessation Treatment during these attempts, not exceeding 10 days total within the past year will be allowed. Checked at V1 and V2.\n* Patient has been advised to quit smoking, informed of smoking risks and of cessation programs as per SoC at V2, and is not willing to quit CIG use for the study duration. Checked at V1 and V2.\n* Patient agrees to be randomized into one of the two study arms. Checked at V2.\n* Patient with confirmed COPD via spirometry performed at V1 (FEV1\u002FFVC \\\u003C70%, post-bronchodilator (-BD)) and COPD severity classified by the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) as GOLD 2 or 3 (30%≤ FEV1 \\\u003C 80% predicted, -BD) with presence of chronic bronchitis (cough and mucus most of the days for \\> three months a year for the two consecutive years prior to the screening visit). Checked at V2.\n* Patient has cough frequency of ≥ 10 cough\u002Fhour during daytime from objective count sensor applied at V1, used to verify eligibility at V2. (Daytime is defined as occurring between 07:00:00 and 22:59:59, based on the local time zone of the site where the patient is assessed.)\n\nExclusion Criteria:\n\n* Patient who self-report concomitant daily use of inhaled cannabis or any type of nicotine containing products other than CIG within the last year.\n* Patient with COPD (moderate or severe) exacerbation that has not resolved according to the GOLD standard (e.g., requirement of additional therapy) or investigator's discretion. Checked at V1 and V2.\n* Patient with currently active cancer or history of any cancer within the last 5 years prior to V1, except for those with basal cell carcinoma of the skin.\n* Patient with acute worsening symptoms of chronic bronchitis or other active respiratory or systemic infections that have not resolved. Checked at V1 and V2.\n* Patient with medical condition(s) that would jeopardize his(her) safety in the context of this study (e.g., safety laboratory parameters, abnormal ECG) or with a condition that would jeopardize study results (e.g., gastroesophageal reflux disease (GERD), heart failure, severe chronic lung emphysema, active symptomatic hay fever), as per Investigator's discretion. Checked at V1 and V2.\n* Patient is legally incompetent, physically, and\u002For mentally incapable of giving consent (e.g., emergency situation, under guardianship, in a social or sanitary establishment, prisoner or involuntarily incarcerated, unable to read).\n* Patient with a history of asthma.\n* Employee of the investigational site or any other party involved in the study, or their first-degree relatives (parent, child, spouse).\n* Current or former employee of the tobacco or e-cigarette industry or their 1st-degree relatives.\n* Patient with active or history of alcohol and\u002For drug abuse within the past year.\n* Patient with positive serological tests for human immunodeficiency virus (HIV) 1\u002F2, hepatitis B or C (Hep B\u002FC).\n* Patient with any concomitant issues (e.g., medical, psychiatric, and\u002For social reason) that, as per Investigator's discretion, would place the study patient at an unacceptable risk for participation in the study.\n* Patient who participated in any trial (for investigational medicine, or other type of intervention) that may have interfered with COPD disease progression and symptoms (including cough and dyspnea) within the last three months as per investigator's discretion.\n* Patient using any systemic (injectable or oral) corticosteroids (acute or chronic treatments) or oxygen therapy in the last 2 months excluding short term use for a COPD exacerbation.\n* Patient currently being treated with angiotensin-converting enzyme (ACE) inhibitors or opioids, or those who have used ACE inhibitors within 4 weeks or opioids within 1 week prior to screening. Checked at V1 and V2.\n* Patient treated with biologic therapies for COPD (e.g., Dupilumab) in the last 6 months.\n* Female patient is pregnant, breastfeeding or lactating, or anticipating becoming pregnant withing the duration of the study. Checked at V1 and V2.\n* Female of childbearing potential who is capable of getting pregnant, defined as a female patient who does not agree to use an acceptable method of effective contraception during the entire study, a female patient that is not surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or tubal ligation) for at least 6 months or postmenopausal (postmenopausal females must have no menstrual bleeding for at least 1 year). Checked at V1 and V2.","40 Years",{"count":395,"type":23},290,[26],"The purpose of this randomized study is to demonstrate direct clinical benefit, i.e., observed benefits in how humans with COPD feel in terms of symptoms (e.g., cough frequency, shortness of breath, and other respiratory symptoms) and function (e.g., lung function, and six-minute walking test \\[6MWT\\]) after switching to THS compared to continuing to smoking cigarettes.",[399,357,30],"COPD",{"date":401,"type":40},"2026-06-15",{"date":403,"type":40},"2025-04-02",{"date":405,"type":23},"2026-11",{"name":407,"class":220},"Philip Morris Products S.A.",112,{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":204,"maxAge":149,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":48},"100539926","little-cigar-oxidants-100539926","NCT06310187","Little Cigar Oxidants","Oxidative Stress and Harmful Constituent Levels Associated With Little Cigars","Inclusion Criteria:\n\n1. Aged 21 - 65 years old\n2. Daily cigarette smoker (\\>= 1 cigarette per day);\n3. Smoke regular, filtered cigarettes or machine rolled cigarettes with a filter\n4. No current or past use of Little Cigars\n5. All other forms of nicotine must be used \\\u003C6 days out of the past 30 days.\n6. Able to read and write in English\n7. No serious cigarette smoking quit attempt or use of any FDA-approved smoking cessation medication in the prior 30 days\n8. No plan to quitting smoking in the next 3 months\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For nursing or trying to become pregnant\n2. Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)\n3. Respiratory diseases (e.g., exacerbations of asthma or Chronic Obstructive Pulmonary Disease (COPD), require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV\u002FAIDS, multiple sclerosis symptoms) or any medical disorder\u002Fmedication that may affect participant safety or biomarker data\n4. Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months\n5. Exhaled Carbon Monoxide (CO) measurement of \\>= 17 parts per million",{"count":151,"type":23},[26],"Determine the effects of little cigars on human exposure to tobacco smoke oxidants. In a balanced randomized cross-over study design in cigarette smokers, subjects will be assigned to 3 exposure groups. These include a high oxidant little cigar exposure condition, a low oxidant little cigar exposure condition, and their usual cigarette. Biological samples will be collected before and after product usage.",[30,376],{"date":380,"type":40},{"date":422,"type":40},"2026-03-25",{"date":424,"type":23},"2029-08",{"name":385,"class":47},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":17,"sex":18,"minAge":204,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":48},"100608281","catalyzing-cigarette-smoking-cessation-through-harm-reduction-sampling-among-people-unmotivated-to-quit-100608281","NCT07199517","Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit","Inclusion Criteria:\n\n1. Able to communicate fluently in English (i.e., speaking, writing, and reading)\n2. Male and female smokers who are \\> 21 years of age and self-report smoking at least 5 cigarettes (menthol and\u002For non-menthol) per day for at least the last 6 months.\n3. Have a carbon monoxide (CO) greater than or equal to 10 ppm\n4. Not using any forms of nicotine regularly other than cigarettes.\n5. Not interested in quitting smoking in the next 30 days.\n6. Capable of giving written informed consent, including compliance with the requirements and restrictions listed in the combined consent and HIPAA form\n\nExclusion Criteria:\n\nSmoking Behavior\n\n1. Regular use of nicotine-containing products other than cigarettes (e.g., chewing tobacco, snuff, snus, cigars, e-cigs, IQOS, ONPS, etc.).\n2. Current or impending (during the study period) enrollment or plans to enroll in a smoking cessation program.\n3. Current use of smoking cessation medication.\n4. Provide a CO breath test reading less than 10 ppm at Intake.\n\nAlcohol and Drug\n\n1. History of substance abuse (other than nicotine dependence) in the past 12 months.\n2. Current alcohol consumption that exceeds 20 standard drinks\u002Fweek.\n3. Current use of recreational drugs (other than nicotine and cannabis)\n\nMedical\n\n1. Women, including all individuals assigned as \"female\" at birth, who are pregnant, breastfeeding, or planning a pregnancy over the duration of the study period.\n2. Serious or unstable disease within the past year (e.g. cancer, uncontrolled hypertension, cardiovascular event).\n\nPsychiatric\n\n1\\. Lifetime history of schizophrenia or psychosis.\n\nGeneral Exclusion\n\n1. Past, current, anticipated, or pending enrollment in another research program over the study period that could potentially impact subject safety, study data, and\u002For the study design as determined by the Principal Investigator.\n2. Any medical condition, illness, disorder, adverse event (AE), or concomitant medication that could compromise participant safety or significantly impact study performance as determined by the Principal Investigator. Subjects may be deemed ineligible for any of the aforementioned reasons at any point throughout the study, as well as during the initial telephone screen.\n3. Significant non-compliance with protocol and\u002For study design as determined by the Principal Investigator and\u002Fo. Subjects may be deemed ineligible at any point throughout the study.",{"count":433,"type":23},472,[26],"This study aims to investigate harm-reduction sampling in a choice format versus medicinal nicotine sampling on smoking behavior, identify mechanisms of sampling's effects, and explore moderators of these effects among a national sample of people unmotivated to quit smoking. Participants will be randomized 2:1 to choose one of two harm-reduction products (ECIG, ONP) versus a medicinal nicotine control condition (nicotine patch + lozenge, NPL), receive a 4-week starter product regimen, and then be followed for 6 months to assess use behavior.",[437,30,438],"Cigarette Smoking","Cigarette Smoking Behavior",[440,441,442,443],"cigarette smoking","harm reduction","sampling","nicotine replacement","2026-06-10",{"date":446,"type":40},"2026-06-11",{"date":448,"type":40},"2026-01-12",{"date":450,"type":23},"2030-07-31",{"name":452,"class":47},"Abramson Cancer Center at Penn Medicine",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":322,"minAge":56,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":172},"100549784","integrating-chws-into-prenatal-care-for-maternal-smoking-cessation-100549784","NCT06438549","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation","Integrating CHWs Into Prenatal Care for Maternal Smoking Cessation: A Pilot Feasibility Study","SFHOPE","Inclusion Criteria:\n\n* \\\u003C 24 weeks pregnant\n* age \\> 18 years,\n* current smokers (100 cigarettes in their lifetime and \\>3 cigarettes per day in the last 7 days; including poly-tobacco use, combining cigarettes with non-combustible products) confirmed by expired carbon monoxide (CO)\n* willing to quit smoking and set a quit date in the next 2 weeks upon enrolling\n* enrolled in prenatal care at Loma Linda University Health (LLUH) or Riverside University Health System (RUHS)\n\nExclusion Criteria:\n\n* severe mental health problems that prevent informed consent and\u002For CHW intervention\n* women who were on Nicotine Replacement Therapy (NRT) or enrolled in a cessation program within 30 days\n* unwillingness to participate in audio-recorded key informant interviews or focus groups",{"count":462,"type":23},105,[26],"This develops a novel behavioral tobacco cessation program for pregnant smokers in San Bernardino County.",[30,90,466],"Tobacco Use in Childbirth",[468,469,470,471,472,473],"prevention","treatment","disparities and social inequality","tobacco use cessation","community health worker","pregnant smokers","2026-06-05",{"date":476,"type":40},"2026-06-08",{"date":478,"type":40},"2024-05-24",{"date":480,"type":23},"2027-08",{"name":482,"class":47},"Loma Linda University",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":18,"minAge":56,"maxAge":149,"enrollmentInfo":489,"targetDuration":4,"studyType":24,"phases":491,"briefSummary":493,"conditions":494,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":172},"100562915","phase-2-neural-mechanisms-connecting-deficient-sleep-and-smoking-relapse-100562915","NCT06609369","Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse","Inclusion Criteria:\n\n* English literate\n* report heavy tobacco use (including nicotine e-cigarettes) for \\>6 months\n* meet biochemical cut off for recent cigarette smoking or e-cigarette use\n* optimal body mass index\n\nExclusion Criteria:\n\n* currently enrolled in other treatments\n* neuropsychiatric exclusions that could interfere with study participation, increase risk of adverse events, and\u002For induce deficient sleep\n* medical contraindications for fMRI, varenicline, and\u002For behavioral treatment\n* factors that cause deficient sleep and for which behavioral treatment has less benefit\n* women who are pregnant or nursing",{"count":490,"type":23},114,[492],"PHASE2","The study aims to investigate whether behavioral interventions promote cessation in adult smokers by ameliorating negative emotions and improving self-control and identify the neural markers of these effects.",[30,188,495],"Insomnia","2026-06-04",{"date":474,"type":40},{"date":499,"type":40},"2025-04-21",{"date":501,"type":23},"2029-06",{"name":103,"class":47},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":17,"sex":18,"minAge":393,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":513,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":525},"100417986","lung-macrophage-populations-and-functions-in-chronic-obstructive-pulmonary-disease-copd-susceptible-smokers-100417986","NCT04722835","Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers","Pre-COPD Pilot","Inclusion Criteria:\n\n* Ages between 40 to 75 years old.\n* History of at least 20 pack-years of smoking.\n* No diagnosis of COPD or asthma.\n* No spirometric evidence of airflow obstruction as determined by FEV1\u002FFVC ratio ≥0.7.\n* FEV1 and FVC \\>lower limit of normal.\n* Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months.\n* Subjects will be divided into two groups by their RV\u002FTLC:\n\nNormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC equal or less than lower limit of normal.\n\nAbnormal RV\u002FTLC Group:\n\n• Plethysmographic RV\u002FTLC higher than lower limit of normal.\n\nExclusion Criteria:\n\n* Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage.\n* Marijuana use \\>400 joints in lifetime or any within past 6 months.\n* Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level.\n* Pregnant\u002Fbreast feeding.\n* Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy.\n* Liver cirrhosis.\n* History of chronic active Hepatitis B or C.","75 Years",{"count":512,"type":23},40,"OBSERVATIONAL","Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.",[516,357,30],"Copd","2026-06-01",{"date":496,"type":40},{"date":520,"type":40},"2021-03-01",{"date":522,"type":23},"2030-12-31",{"name":524,"class":47},"University of California, San Francisco",3,{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":513,"phases":4,"briefSummary":534,"conditions":535,"keywords":541,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":48},"100557265","the-efficacy-of-conventional-screening-versus-mhealth-screening-in-early-detection-of-oral-potentially-malignant-disorders-and-oral-cancer-amongst-the-rural-population-of-varanasi-a-prospective-and-blinded-study-100557265","NCT06535867","The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study","Inclusion Criteria:\n\nPositive for any one or more of the following:\n\n* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and\u002For regular use of alcohol)\n* Clinical signs\u002Fsymptoms (non-healing ulcers, white\u002F red\u002Fred \\& white patches in the mouth, restriction of mouth opening and swelling of the neck)\n* All individuals aged above 40 irrespective of habit\u002Foral lesions\n\nExclusion Criteria:\n\n* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer\n* Under treatment for tuberculosis or suffering from any acute illness\u002F debilitating systemic disorders",{"count":533,"type":23},5122,"Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India",[357,536,537,538,30,358,539,540],"Smoking, Cigarette","Smoking, Tobacco","Betel Chewer's Mucosa","Alcohol Drinking","Smokeless Tobacco Hyperkeratosis",[126,542,543,544,545,546,547,548,549,550],"smoking, cigarette","smoking, tobacco","smokeless tobacco","betel leaf","areca nut","paan masala","alcohol use","Memorial Sloan Kettering Cancer Center","24-148","2026-05-19",{"date":553,"type":40},"2026-05-22",{"date":555,"type":40},"2024-07-30",{"date":557,"type":23},"2031-07-30",{"name":549,"class":47},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":24,"phases":567,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":48},"100581563","developing-a-scalable-tobacco-cessation-program-for-cancer-survivors-and-caregivers-100581563","NCT06851936","Developing a Scalable Tobacco Cessation Program for Cancer Survivors and Caregivers","Inclusion Criteria:\n\nCancer Survivors including Current Cancer Patients\n\n* Current self-reported user of any tobacco\u002Fnicotine product at time of baseline screening assessment (e.g., cigarettes, e-cigarettes, cigars, dip\u002Fchew) in the past month.\n* Any history of cancer diagnosis. Subjects currently receiving cancer-related treatments are eligible for enrollment.\n* Receiving care from the participating UF Health clinics (Medical Oncology, Urology, and Radiation Oncology).\n* Capable of completing study requirements\n* Informed consent obtained from the subject and documentation of subject agreement to comply with all study-related processes\n* Adults aged ≥18 years\n\nInformal Caregivers\u002FFamily Members of Cancer Survivors\n\n* Current self-reported user of any tobacco\u002Fnicotine product at time of baseline screening assessment (e.g., cigarettes, e-cigarettes, cigars, dip\u002Fchew) in the past month.\n* A family member, informal caregiver, or friend of an enrolled cancer survivor receiving care from the participating UF Health clinics as described above\n* Capable of completing study requirements\n* Informed consent obtained from the subject and documentation of subject agreement to comply with all study-related processes\n* Adults aged ≥18 years\n\nExclusion Criteria:\n\nCancer Survivors including Current Cancer Patients\n\n* Patients unable to complete the sessions because of language, travel or technology barriers\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.\n\nInformal Caregivers\u002FFamily Members of Cancer Survivors\n\n* Participants unable to complete the sessions because of language, travel or technology barriers\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.",{"count":566,"type":23},204,[26],"Given the challenges to delivering tobacco cessation treatment in oncology care and the unique challenges faced by individuals attempting to quit tobacco after a cancer diagnosis, scalable cessation programs that are tailored to the experiences of cancer survivors that also integrate caregiver\u002Ffamily support are needed. To address this need, this study will use an intervention that consists of two primary strategies: 1) a tailored cessation program for cancer survivors and family members\u002Fcaregivers who use tobacco and 2) healthcare provider training.\n\nHealthcare providers will receive training on the AAC model (Ask patients about tobacco use, Advise patients to quit, Connect patients to cessation resources), including materials focused on tobacco cessation in cancer care from the CDC, as well as a brief evidence-based communication skills training based on the C-LEAR (Counsel, Listen, Empathize, Answer, Recommend) approach.",[570,30],"Nicotine Use",[572,573,574,330,575],"tobacco cessation","AHEC","cancer survivors","nicotine","2026-05-14",{"date":578,"type":40},"2026-05-15",{"date":580,"type":40},"2025-07-11",{"date":582,"type":23},"2026-10-21",{"name":584,"class":47},"University of Florida",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":17,"sex":18,"minAge":204,"maxAge":205,"enrollmentInfo":592,"targetDuration":4,"studyType":24,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":599,"leadSponsor":601,"locationsCount":4},"100639243","abuse-liability-of-two-modern-oral-nicotine-pouched-products-100639243","NCT07595055","Abuse Liability of Two Modern Oral Nicotine Pouched Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) via dipstick at Screening and at Check-in Day 1.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.",{"count":512,"type":23},[26],"This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[357,210,30,358],"2026-05-12",{"date":551,"type":40},{"date":401,"type":23},{"date":600,"type":23},"2026-11-30",{"name":219,"class":220},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":274,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":172},"100605470","cigar-legislation-and-regulation-in-tobacco-for-the-young-project-clarity-100605470","NCT07162935","Cigar Legislation and Regulation in Tobacco for the Young (Project CLARITY)","Addiction Potential, Flavoring Content, and Substitutability of Concept Flavored Cigarillos","CLARITY","Inclusion Criteria:\n\n1. Ages 18 to 24\n2. Report past 30-day use of a cigarillo\n3. Ability to read English at least an 8th grade level\n4. No immediate plans to quit using tobacco\n5. At least 1 prior experience with a flavored tobacco product\n6. U.S. Citizen or permanent resident of the United States.\n\nExclusion Criteria:\n\n1. Current use of smoking cessation pharmacotherapy or nicotine replacement therapy;\n2. Pregnant, planning to become pregnant, or currently breastfeeding;\n3. Past or current clinically significant heart disease or hypertension, or other smoking-related disease that could preclude successful study completion;\n4. Inability to abstain from nicotine\u002Ftobacco products for at least 12 hours\n5. Unwillingness to use the research cigarillos in the lab",{"count":180,"type":23},[26],"This clinical trial will recruit young adults who currently use cigarillos and examine the smoking behavior and perceptions of different flavored cigarillos, product ingredients\u002Fadditives impacting these perceptions, and simulated tobacco use outcomes (quitting, switching) in various policy scenarios where different types of flavors are available on the market.",[614,30],"Cigar Smoking","2026-05-07",{"date":617,"type":40},"2026-05-11",{"date":619,"type":40},"2026-02-23",{"date":621,"type":23},"2030-05-31",{"name":623,"class":47},"University of Oklahoma",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":17,"sex":18,"minAge":204,"maxAge":149,"enrollmentInfo":630,"targetDuration":4,"studyType":24,"phases":632,"briefSummary":633,"conditions":634,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":48},"100483256","linking-brain-network-dynamics-to-imminent-smoking-lapse-risk-and-behavior-100483256","NCT05572671","Linking Brain Network Dynamics to Imminent Smoking Lapse Risk and Behavior","Inclusion Criteria:\n\n* Participants must be between the ages of 21 and 65.\n* Participants must be fluent English speakers.\n* Participants must pass an MRI safety screening.\n* Participants must report smoking at least six cigarettes per day continuously for at least the 12 preceding months.\n* Participants must have a baseline expired-air carbon monoxide exceeding 10 parts per million in order to verify smoking status.\n\nExclusion Criteria:\n\n* Individuals will be excluded if they report that they are not willing to refrain from using nicotine for 12 hours before the experimental lab visit.\n* Individuals will be excluded if they have any known risk from exposure to high-field strength magnetic fields (e.g., pacemakers), any irremovable metallic foreign objects in their body (e.g., braces), or a questionable history of metallic fragments that are likely to create artifact on the MRI scans.",{"count":631,"type":23},150,[26],"Most attempts to quit smoking end in relapse, or a return to regular smoking. One of the biggest threats to cessation is a lapse (i.e., any cigarette use during a quit attempt). Thus, characterizing why lapses occur is essential to understanding and preventing smoking relapse. Functional magnetic resonance imaging (fMRI) is a promising method for characterizing the psychological processes that lead to smoking lapses because it provides a way to measures patterns of brain activity thought to reflect relevant mental processes as they change over time. However, methodological issues have hindered the ability to capitalize on this potential and prevented an understanding of how brain activity and corresponding psychological processes unfold in the critical moments that immediately precede a smoking lapse. The proposed project will address this knowledge gap using a novel fMRI paradigm adapted from a well-validated behavioral lapse task. The goals of the project are to characterize changes in brain activity that lead up to a lapse and to investigate how these changes are related to concurrent affect and subsequent cigarette use.",[357,30],"2026-04-29",{"date":637,"type":40},"2026-05-05",{"date":639,"type":40},"2023-04-04",{"date":480,"type":23},{"name":642,"class":47},"Penn State University"]